Over the last 10 yr, multiparametric magnetic resonance imaging (mp-MRI) has been suggested as a diagnostic test capable of detecting and ruling out clinically significant gland-confined prostate cancer before biopsy. The poor methodologic quality of many initial studies [@bib0100], [@bib0105] led to the need for a large robust programme of research to evaluate its clinical validity and utility within the pathway [@bib0110]. The PICTURE [@bib0115] and Prostate MR Imaging Study (PROMIS) [@bib0110] trials met this research need.

Although there has been significant improvement in the literature on mp-MRI, there remain limitations when evaluating clinical validity (sensitivity, specificity, and positive and negative predictive values). For instance, many recent publications have limited sample sizes [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140], [@bib0145] with no a prior power calculations. Many used histologic reference standards such as transrectal ultrasound (TRUS) biopsy [@bib0150], [@bib0155], [@bib0160], MRI-guided biopsy, and/or limited sampling with the biopsy operators unblinded to the MRI results [@bib0145], [@bib0165], [@bib0170]. Other studies only triggered biopsies when there was an abnormality on mp-MRI [@bib0120], [@bib0130], [@bib0135], [@bib0140]. This limits the ability to comment on negative predictive value and introduces operator bias. These factors, among others such as changing technology, reader variability, and variable mp-MRI practice and protocols, contributed to the variability of results on meta-analysis [@bib0175], [@bib0180].

PROMIS [@bib0110] is a multicentre paired-cohort diagnostic trial funded by the National Institute for Health Research Health Technology Assessment and Prostate Cancer UK. A total of 714 biopsy-naïve patients are undergoing optimised guideline-compliant [@bib0185] mp-MRI followed by combined 5-mm transperineal mapping biopsies and a 12-core TRUS biopsy under general anaesthetic in the same setting.

PROMIS will provide level 1b evidence [@bib0190] on the accuracy of mp-MRI that overcomes the limitations of the current literature [@bib0110]. PROMIS will assess the costs and cost-benefit of a prebiopsy MRI pathway ([Fig. 1](#fig0005){ref-type="fig"}), as well as interobserver variability. Among other outcomes biobanking of serum, plasma, whole blood, and urine will provide samples for the development and validation of biochemical markers.

This diagnostic trial set up in multiple centres proved to be a challenge, with many unforeseen obstacles.•*Scanner set-up and qualification:* PROMIS uses 1.5-T scanners, the most readily available in most centres. Each scanner had to be optimised in each centre in conjunction with the lead centre in an iterative manner over sometimes weeks and months. We noted significant differences between scanners from the same manufacturer, and even scanners of the same model. These differences required further changes to imaging parameters to remain compliant with international guidelines; one scanner by a certain manufacturer had to be excluded from the study as we were unable to obtain acceptable diffusion sequences after several iterations. These factors will allow us to assess how variations in scanner make, model, and condition may impact on subsequent diffusion and dissemination within the UK and beyond.•*Lack of essential MRI and interventional ultrasound skills:* To assure correct implementation of a standardised operating procedure in each trial intervention, the lead radiologist formally trained the participating radiologists and held several formal and informal meetings since trial inception to maintain quality control and address issues as they arose. Similarly, each site was required to observe the combined biopsy procedure at trained sites and subsequently required supervision of the conduct of the biopsies.•*Running a surgical trial:* As a surgical interventional study, issues with respect to resource use arose. First, the mp-MRI standardisation process revealed that some centres were not using gadolinium dynamic contrast enhancement, and the additional 15 min of scan time impacted on scanner capacity. Second, the combined biopsy procedure required between 60 and 90 min of operating theatre time. Third, with a growing body of literature pointing to the positive role of mp-MRI, there were an increasing number of physicians and patients lacking equipoise for the trial.

PROMIS recruitment is on track, with only a 6-mo extension to our original predicted end date. From 11 centres across the UK, 578 patients have been recruited and 98 have withdrawn up to April 2015. Recruitment is due to end in October/November 2015.

PROMIS will provide an once-in-a-lifetime opportunity to evaluate the diagnostic accuracy of mp-MRI based on an adequately large sample size and a highly accurate reference test in comparison to standard TRUS biopsy. The biobank of tissue, imaging data, serum, and urine will offer a uniquely validated data set for further translational research.
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Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.euf.2015.04.007](10.1016/j.euf.2015.04.007){#intr0005}.

![Potential clinical impact of the PROMIS study. mp-MRI = multiparametric magnetic resonance imaging; TRUS = transrectal ultrasound; signif = significant.](gr1){#fig0005}
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